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Abstract 
A central challenge faced by biological and medical research is to understand the impact of 
chemical entities on living cells. Identifying the relationships between the chemical structures 
and their cellular responses is valuable for improving drug design and targeted therapies. The 
chemical structures and their detailed molecular responses need to be combined through a 
systematic analysis to learn the complex dependencies, which can then assist in improving 
understanding of the molecular mechanisms of drugs as well as predictions on the effects of 
unknown molecules. Moreover, with emerging drug-response data sets being proﬁled over 
several disease types and phenotypic details, it is pertinent to develop advanced computational 
methods that can be used to study multiple sets of data together. 
In this thesis, a novel multi-disciplinary challenge is undertaken for computationally 
analyzing interactions between multiple biological responses and chemical properties of drugs, 
while simultaneously advancing the computational methods to better learn these interactions. 
Speciﬁcally, multi-view dependency modeling of paired data sets is formulated as a means of 
systematically studying the drug-response relationships. First, the systematic analysis of drug 
structures and their genome-wide responses is presented as a multi-set dependency modeling 
problem and established methods are adopted to test the novel hypothesis. 
Several novel extensions of the drug-response analysis are then presented that explore 
responses measured over multiple disease types and multiple levels of phenotypic detail, 
uncovering novel biological insights of potential impact. These analyses are made possible by 
novel advancements in multi-view methods. Speciﬁcally, the ﬁrst Bayesian tensor canonical  
correlation analysis and its extensions are introduced to capture the underlying multi-way 
structure and applied in analyzing novel toxicogenomic interactions. The results illustrate that 
modeling the precise multi-view and multi-way formulation of the data is valuable for 
discovering interpretable latent components as well as for the prediction of unseen responses 
of drugs. 
Therefore, the original contribution to knowledge in this dissertation is two-fold: ﬁrst, the 
data-driven identiﬁcation of relationships between structural properties of drugs and their 
genome-wide responses in cells and, second, novel advancements of multi-view methods that 
ﬁnd dependencies between paired data sets. Open source implementations of the new methods 
have been released to facilitate further research. 
Keywords Bayesian modeling, Machine learning, Multi-view learning, Computational biology, 
Bioinformatics, Toxicogenomics, Latent variable models, Bayesian tensor CCA 
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1. Introduction
One of the fundamental challenges for life sciences in general, and medicine
in particular, is to understand how chemical entities in food, medicines,
and environment affect living cells. This is difﬁcult because the chemicals
are expected to produce multiple and overwhelmingly diverse responses.
Genome-wide measurements of these responses such as the gene expres-
sion, can provide insights into the system-level understanding and action
mechanisms [1, 2]. With millions of available compounds and the mul-
titude of responses of cells, understanding the effects of drugs is a chal-
lenging yet signiﬁcantly important goal. A key challenge here is to learn
the complex dependencies between the structures and their genome-wide
responses. These dependencies can assist in better understanding the ef-
fects of drugs, as well as to make predictions of effects for previously un-
seen molecules. Therefore, if uncovered, these dependencies may assist in
signiﬁcantly enhancing optimization efforts on design, re-purposing and
personalized applications of the drugs.
Traditionally, cellular response data has been scarce and has hosted
only a few samples. These limited measurements have been only par-
tially relevant as they present a view of the response to speciﬁc condi-
tions only. With advancements in high-throughput response measure-
ment techniques, data sets are being proﬁled that measure genome-wide
effects of chemical perturbations on multiple specialized cells [3]. This
knowledge offers the opportunity to study the diverse responses, over sev-
eral different cell-types in a systematic fashion.
One plausible direction is to harness the existing measurement data
and apply computational approaches to predict the relationships between
structural aspects of the drugs and the observed systems-wide biological
responses. On the computational front, machine learning is playing an
important role in developing methods to analyze data. Lately, Bayesian
11
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machine learning has become increasingly valuable allowing principled
means of handling uncertainty in the model parameters and incorpora-
tion of the prior probabilities, which make it possible to study data even
with small sample sizes. In this work, generative latent variable models
enable building representations that explain the processes that have gen-
erated the observed data [4, 5]. By discovering the descriptions of these
underlying processes, one can potentially understand them or produce the
required predictions.
When the task is to search for relationships between two or more vari-
ables, machine learning approaches that model dependencies among vari-
ables ﬁt the goal directly. These methods seek co-occurring patterns that
relate the variables of interest. Component-based dependency models are
additionally able to segregate multiple distinct dependencies existing in
the data. For example, factor analysis is a commonly used method that
captures dependencies between variables into distinct factors, with each
factor capturing different dependencies [6, 7]. Methods such as the canon-
ical correlation analysis [CCA; 8, 9] identify dependencies between two
data sets, decomposing them into distinct components. Recent advances
in Bayesian factor analysis and canonical correlation analysis have made
them practically applicable in many real-world scenarios [10, 11].
The central hypothesis of this dissertation is that component-based
dependency modeling can be used to systematically study the systems-
wide responses of cells to drugs and their structures, uncovering the links
between them in a data-driven fashion. Here the basic assumption is
that the common statistical patterns existing between the datasets repre-
sent underlying mechanistic processes. These processes are hypothesized
to be informative for the action mechanisms of the drugs, i.e. the bio-
chemical interactions through which a drug produces its pharmacological
effect. Analyzing the responses of multiple types of cells brings up the re-
quirement for new multi-source methods. Moreover, even more structured
methods are needed for studying hypothesis that emerge when responses
are measured at several levels of phenotypic details. This thesis starts
by adapting canonical correlations for the structure-response modeling to
test the basic premise. It then presents several novel multi-source models
that remove some of the limitations of existing methods and applies them
to novel drug response analysis problems.
Typically, the action mechanisms of drugs have been studied compu-
tationally using chemical properties of the drugs or biological properties
12
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of the speciﬁc targets [12]. Approaches such as the quantitative structure-
activity analysis (QSAR) commonly use structural properties of the drugs
to predict their biological activity. For example, the classical QSAR work
by Cramer et al. [13] predicted a single biological activity from structural
features of the drugs. However, recent evidence suggests the importance
of tailoring the drugs for multiple targets to enhance their efﬁcacy [14].
Moreover, drugs interacting with several targets may also produce toxic-
ity and other side effects. Therefore, balancing the efﬁcacy vs. toxicity is a
crucially important problem. On the other hand, genome-wide responses
to drugs have also been successfully used in explaining the mechanisms of
drug actions [15, 16]. However, to the best of our knowledge, the system-
atic integration of these complementary approaches, to study structure-
response relationships with component-based dependency models, has not
been explored earlier.
Therefore, this research is positioned at the intersection of three dif-
ferent ﬁelds: machine learning, bioinformatics, and chemoinformatics.
1.1 Contributions and Organization of the thesis
This thesis presents several novel multi-view dependency modeling meth-
ods and explores their applicability for the data-driven decomposition of
drug structure-response links. The applications utilize the drug response
interactions for both understanding the underlying processes and the pre-
diction of unseen responses.
Publication I adapts the existing canonical correlation model family,
hypothesizing the latent components as descriptions of underlying drug
response mechanisms. This formulation extends the drug response anal-
ysis from standard QSAR, which relates drug properties with their uni-
variate responses, to ﬁnding relationships between structural descrip-
tors of the drugs and their genome-wide responses. The paper demon-
strates that component-based dependency modeling can successfully cap-
ture structure-related drug response patterns in a data-driven fashion.
Publications II and III generalize the analysis to multiple diseases,
with novel multi-view model formulations. Speciﬁcally, the group factor
analysis (GFA) model carries out a data-driven search for relationships
between the chemical properties of the drug molecules and their disease-
speciﬁc biological response proﬁles. The relationships governed by dis-
tinct underlying biological processes are segregated automatically by the
13
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sparse factorization. This ability of GFA makes it possible to distinguish
between responses that are disease-speciﬁc from those common to all the
disease types analyzed. A focused experiment was carried out to study
this in Publication II. When exposed to genome-wide data sets, a criti-
cal challenge for algorithms is the high dimensionality and small sample
size of the data. The small number of samples leave considerable un-
certainty in the data, and prioritizing the interacting features becomes a
major concern. In Publication III, feature-level sparsity is applied in GFA
to cater for these concerns, and a detailed structure-response analysis is
performed. The study demonstrated that data-driven modeling of drug
responses in multiple diseases can be informative for identifying estab-
lished and novel structure-response links, as well as for exploring disease-
speciﬁc action mechanisms. Such systematic large-scale studies can also
identify new repositioning opportunities for existing drugs. If validated
with wet lab experiments, the approach may also open up the opportunity
for drug designers to tailor drug molecules based on the genome-wide re-
sponses of existing drugs.
Publication IV addresses the analogous problem of predicting drug
targets from a multi-source formulation. The paper advances the state
of the art by concluding that protein targets of the drugs can be better
predicted when multiple types of descriptions of the drugs are used as
side information sources.
Publication V introduces a new problem formulation and presents a
model called Bayesian multi-view tensor factorization (BMTF) for solving
it. BMTF learns dependencies between multiple co-occurring tensors com-
prehensively, decomposing them into a set of underlying factors that can
be shared between some or all of the tensors. This paper advances the
state of the art by making it possible to jointly factorize the multi-view
tensor data sets. In short, there is now a model similar to Bayesian CCA
but for tensors. The method is applied to decompose drug responses of
multiple diseases at different levels of phenotypic detail, helping applica-
tion experts to construct targeted hypotheses for the underlying processes
generating the data.
Publication VI presents a new model for joint factorization of mul-
tiple matrices and tensors, coined multi-tensor factorization (MTF). The
method generalizes the matrix-tensor factorization to novel Bayesian multi-
view settings as well as factorization of arbitrary sets of tensors. The
model factorizes multiple matrices and tensors collectively, allowing in-
14
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vestigation of relationships that may exist between some or all of them.
The new model also addresses several key practical issues in a princi-
pled fashion. The Bayesian formulation provides improved performance
in real-world applications with small samples and large dimensions of the
matrix-tensor data sets. The paper ﬁnally presents the decomposition of
structurally driven responses of multiple diseases when integrating re-
sponses from various levels of phenotypic detail. Thereby, demonstrating
that the method can assist application scientists to explore and predict
drug response mechanisms, by integrating the data sets of choice.
Chapter 2 discusses the matrix and tensor factorization methods that
form the basis of this thesis. In particular, it presents the relevant as-
sumptions of these approaches that are harnessed for both the applica-
tions and machine learning advancements. Chapter 3 discusses the bio-
logical responses to drugs, the measurement data sets, and the structural
properties of chemical compounds. Chapters 4 and 5 present the main
contributions of the thesis, describing the different multi-source models
while increasing the amount of structure they capture as the thesis pro-
gresses. The chapters simultaneously discuss the corresponding novel
drug response analysis that is made possible by the advanced methods.
Chapter 6 concludes the thesis and suggests directions for further re-
search.
15
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2. Bayesian machine learning and
factorizations
Machine learning focuses on algorithms that search for patterns in the
data and extract useful information [5]. The algorithms learn a model
from existing data samples and utilize it for various tasks. In several
applications, the data measurements can be hypothesized to have been
generated from an underlying process that may not be measurable itself
[17]. Moreover, the measurements are typically high-dimensional and
may contain correlated variables which are additionally corrupted with
noise, making the direct analysis complicated. One of the key features of
machine learning is to learn low-dimensional latent representations that
summarize the data. The learned data summaries can then be hypothe-
sized as the descriptions of the phenomenon that have generated the data.
These summaries are then commonly used to understand the mechanisms
of the data generation process, or then to predict the unseen outcomes. A
salient latent summarization techniques is data factorization that forms
the core of all the methods developed in this thesis. This chapter describes
data factorization approaches, identifying the key assumptions and the
latest developments.
2.1 Latent variable models
Latent variable models are a powerful approach to machine learning [4,
18]. They provide a ﬂexible way of describing dependencies between the
data variables by assuming that the observed data was generated through
the interactions of a few unobserved (latent) variables. These latent vari-
ables present a low-dimensional summary of the observed data and can
be considered as concise and denoised descriptions of the underlying pro-
cesses that have generated the data. The representations can then be
used to understand the data generation processes or predict the unob-
17
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served data entities.
Formally, the higher-dimensional data variables x ∈ RD can be repre-
sented using lower-dimensional latent variables z = {z1, z2, . . . zK} where
K < D, providing a ﬂexible way to represent the dependencies between
the observed variables. The number of latent variables is typically much
smaller than the data dimensionality and each zk usually follows a simple
distribution.
The matrix and tensor factorization methods discussed in the follow-
ing sections are key examples of latent variable models that ﬁnd low-
dimensional factors (latent variables) to represent the high-dimensional
observed data.
2.2 Matrix factorization and co-occurring patterns
Matrix factorization (MF) is a well-established approach having vast sci-
entiﬁc applicability including missing value prediction, dimensionality re-
duction, and data visualization [19–21]. Among other motivations, matrix
factorization can be seen as a means of identifying underlying processes
that produced the data. In such a scheme, measurements are thought
to have been generated from a combination of multiple latent processes,
each generating some parts of the data. For matrix factorization, the task
is to decompose a matrix into several factors or components that describe
the underlying (hopefully meaningful) processes. The terms factors and
components are used interchangeably in this thesis, as both have been
commonly used in the literature.
A broad set of approaches has been studied to factorize matrices, op-
timizing on different criteria [22, 23]. For factorization of a single matrix
factor analysis, and for joint factorization of two matrices canonical cor-
relation analysis, are well-established methods. Both factor analysis and
canonical correlation analysis form the basis of all the methods developed
and presented in this thesis, and are described next.
Factor Analysis (FA) [6] is an unsupervised technique for low-dimensional
factorization of a single matrix. FA assumes that the data matrix X ∈
RN×D can be modeled by a latent factor representation such that the fac-
tors capture dependencies between the variables. For N samples, each
18
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described by a D-dimensional data vector xn, FA can be represented as
xn ∼N(Wzn,Σ) (2.1)
zn ∼N(0, I) ,
where Wzn is a low-dimensional latent representation of xn, while Σ is a
diagonal noise covariance matrix, with a separate term σ1, . . . , σD for each
of the D variables. The noise model captures the individual variation of
each variable, and the latent representation Wzn models the covariance
patterns between the variables. This assumption is of key importance
as it allows FA to capture patterns common between two or more vari-
ables. In contrast, principal component analysis [PCA; 20] assumes the
more restrictive isotropic noise model with all the variables having a sin-
gle variance parameter.
Bayesian factor analysis has been used successfully in modeling the
factors from real data applications. For example, in modeling genomic
data sets, the low-dimensional factors are used to represent the biological
processes driving the mechanisms. Recently, several studies have been
conducted using microarray gene expression data sets to create hypothe-
ses for the cellular response patterns [7, 10, 24]. Similarly, learning the
denoised low-rank structure with factorization has also been proved use-
ful for the prediction of missing values [19, 25].
Canonical Correlation Analysis (CCA) [8] is an unsupervised method
that decomposes two paired matrices into a shared low-dimensional rep-
resentation. The paired matrices are characterized by having a common
identity of the samples. Therefore, unlike FA that ﬁnds dependencies be-
tween two or more variables, CCA aims to capture the correlated patterns
between two matrices. CCA linearly transforms the matrices into a max-
imally correlated subspace of components, such that any two components
are uncorrelated with each other. This way, it can ﬁnd distinct compo-
nents that are common to both of the matrices. For two data vectors x(1)n
and x(2)n , CCA can be represented as a generative process [11, 26]:
x(m)n ∼N(W(m)zn,Ψ(m)) m = 1, 2 (2.2)
zn ∼N(0, I) ,
where zn is the latent vector common to both matrices, W(m) are load-
ings for each matrix, and Ψ(m) the corresponding noise covariance matrix.
The shared latent representation zn of CCA models the covariation pat-
terns between the two matrices, while Ψ(m) models the variation speciﬁc
19
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to each matrix. This division implies that zn can capture the dependencies
between the two matrices. An efﬁcient CCA solution using group-sparse
priors was recently presented by [11]. Their formulation uses the latent
variables to represent both the correlated patterns between the matrices
as well as the matrix speciﬁc variation, while the noise covariance is as-
sumed isotropic for each of the data sets.
For a comprehensive review of Bayesian canonical correlation analy-
sis see [11], while [9] for classical CCA. CCA has been successfully used
for modeling dependencies between data sets. For example, in genomics
it has been used to identify chromosomal regions showing dependencies
in copy number and gene expression of a set of samples [27, 28].
2.3 Tensor factorizations
When data sets have more dimensions than just samples and features,
they may present tensorial relationships. While matrix factorization meth-
ods are optimized to decompose matrices, the structure in more than two
modes can be handled appropriately by tensor factorizations. In order to
capture the more structured patterns of such data sets and avoid overﬁt-
ting, tensor methods use more constrained formulations that have fewer
parameters than their matrix counterparts.
Analogous to MF, tensor factorizations perform decompositions of the
tensors into their constituent parts. However, the decompositions of multi-
mode data sets allow factorizations with several different interaction as-
sumptions and present additional modeling issues. Consequently, a wide
range of low-dimensional representations of tensors have been proposed
in the literature [29]. The most well-studied models include the CAN-
DECOMP/PARAFAC [30, 31] and the Tucker model family [32]. For a
comprehensive review of tensor factorizations and their properties, see
[29].
Tensor factorizations have obtained signiﬁcant success in chemomet-
rics and psychometrics in the last decade. Recently, they have also been
adopted in bioinformatics and related application ﬁelds. For example,
tensor methods have been used in exploring factors of gene expression
patterns over replicates of several stimuli [33], as well as integrating re-
sponses from different studies [34, 35]. The rapid accumulation of bi-
ological measurement data is leading to new and extended hypotheses,
which may be investigated with tensor formulations. Very recently, gene
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Figure 2.1. Top: CANDECOMP/PARAFAC (CP) factorizes a tensor X into K compo-
nents in each mode and is equivalent to sum of rank one component tensors.
Bottom: Tucker-1 and Tucker-3 decompositions that factorize the tensors in
one and three modes, respectively. Tucker-3 models the interactions between
components via a core tensor G.
expression time series of several samples [36] and integrative analyses
of metabolic and gene expression networks [37] have also been explored
with tensor factorizations.
2.3.1 CANDECOMP/PARAFAC (CP)
The CP decomposition was presented independently as canonical decom-
position (CANDECOMP by [30]) and parallel factor analysis (PARAFAC
[31, 38]). CP is a direct extension of matrix factorization to higher order
data sets. The decomposition originates from Cattell’s theory of paral-
lel proportional proﬁles [39]. Cattell stated that two independent real-
izations of similar data sets could be decomposed jointly with a simulta-
neous factor analysis. This process learns a common projection matrix
that differs only in the scale of factors for the two data sets and captures
the intrinsic axis of the underlying factors. Parallel factor analysis [31]
extends this conceptualization to a tensor (a set of matrices placed to-
gether), allowing the projections of FA to differ only in their scales in the
third mode. CP can therefore be seen as multiple factor analysis of a sin-
gle phenomenon being performed simultaneously, to infer the empirically
meaningful factors.
The CP decomposition is deﬁned in a symmetric way to factorize a
tensor into a sum of rank-one tensors, where each rank one tensor is the
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outer product of vector loadings in all modes (Figure 2.1-top). For a third-
order tensor X ∈ RN×D×L, a rank-K CP is represented as:
X =
K∑
k=1
zk ◦wk ◦ uk +  , (2.3)
where Z ∈ RN×K and U ∈ RL×K and W ∈ RD×K are the latent variables
corresponding to the three modes.
This component decomposition is valuable for many applications, as
the different rank-1 terms can be related to separate mechanisms that
may have contributed to the higher order tensor, making the model read-
ily interpretable. Furthermore, the CP factorization solutions are known
to be unique up to a given permutation and scaling [40]. These character-
istics of CP, make it a suitable choice for the underlying tensor factoriza-
tion in the methods presented in this thesis.
Commonly, CP is solved for a given K via Alternating Least Squares
(ALS) algorithm [41, 42]. ALS ﬁnds a locally optimal CP solution by up-
dating one loading matrix at a time while keeping others ﬁxed [29]. It
estimates the parameters by a least squares approach that is equivalent
to maximum likelihood estimate under the assumption of isotropic Gaus-
sian noise. Recently, several authors have also solved CP in a Bayesian
setting demonstrating its advantage [43–45].
Rank. Unlike matrix factorizations, in CP the exact rank determination
can be crucially important as both under and over-estimation may result
in invalid solutions [29]. The primary reason is that a rank-k CP solution
is not guaranteed to be the best rank-k approximation if the true number
of factors is larger than k [46]. On the other hand, the factorization could
produce artiﬁcial splits or noise components if k is set larger than the
actual value. Therefore, the best rank-k solution can not be computed
sequentially, rather all the factors must be found simultaneously [29].
Determining the CP rank is a challenging problem and solutions based
on cross-validation tend to be computationally expensive [47]. Recently,
a Bayesian solution for automatic rank identiﬁcation has been proposed
[44], which is also computationally fast, however, its robustness could be
further studied.
Degeneracy. Practical application of CP can occasionally suffer from
degenerate solutions, in which two or more components become highly
correlated in all the modes and some of the loading values becoming arbi-
trarily large. The degenerate solutions are not interpretable and compli-
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cate the use of CP [48]. These degeneracies have primarily been observed
when data sets having a non-trilinear structure are decomposed with CP
[49, 50]. Nevertheless, the strong interpretative power of CP has brought
up degeneracies as an important research topic [51–53]. As high neg-
ative correlations are a primary characteristic of degeneracies, several
researchers have recently studied solutions with strict constraints that
force uncorrelatedness, such as orthogonality and non-negativity [52, 53].
2.3.2 Tucker
The Tucker model family [32] deﬁnes several levels of factorization, and
has three main forms, Tucker-1, Tucker-2, and Tucker-3. The 1-mode fac-
torization of Tucker, is the most relaxed formulation that decomposes only
one of the modes while Tucker-2 and Tucker-3 factorize two and all three
of the modes, respectively. Tucker-1 being the most ﬂexible is also equiva-
lent to matrix factorization of a matricized tensor (Figure 2.1, bottom-left).
On the other hand, Tucker-3 enforces more structure and is characterized
by interactions between a different set of factors in each mode (Figure
2.1, bottom-right). Unlike in CP, in the Tucker-3 model, a factor does not
represent an additive source of information; rather, it represents a pat-
tern of variation in a given mode only, and the factors are thought to have
generated the data by interacting with several other patterns of variation
(factors),
X ≈
P∑
p=1
Q∑
q=1
R∑
r=1
gp,q,rzp ◦wq ◦ ur .
The loadings Z ∈ RN×P , W ∈ RD×Q and U ∈ RL×R are accompanied
with a core tensor G ∈ RP×Q×R that captures the interactions between
factors of different modes (Figure 2.1, bottom-right). The complex inter-
action of factors via G makes interpretation of factors difﬁcult. Moreover,
in contrast to the CP factorization, the Tucker model is not guaranteed
to provide unique solutions. The Tucker component matrices can be ro-
tated, and the core tensor G counter-rotated to obtain inﬁnite number of
models with an equal ﬁt. This rotational ambiguity requires additional
constraints to make the solutions interpretable [54, 55]. However, CP
can be seen as a restricted version of Tucker-3 with the core tensor G con-
strained to be a superdiagonal and of size K×K×K. While Tucker better
ﬁts complex structures, the CP outperforms it when the data contains tri-
linear relationships [56].
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Table 2.1. The novel methods applied or developed in this thesis are based on matrix or
tensor factorizations as summarized in this table. The matrix factorization
methods of Publications I-IV are discussed in Chapter 4 while tensor factor-
ization methods of Publications V-VI are described in Chapter 5.
Pub. Matrix Factorization Tensor Factorization
I Canonical Correlation Analysis
II Group Factor Analysis
III Sparse Group Factor Analysis
IV Kernelized Bayesian Matrix
Factorization
V Bayesian Multi-view Tensor
Factorization
VI Multi-tensor Factorization Multi-tensor Factorization
This thesis utilizes and develops novel extensions of matrix and ten-
sor factorization methods, when multiple data sets are factorized together.
The methods are detailed in Chapters 4 and 5, however, a summary of
their matrix or tensor nature is presented in Table 2.1.
2.4 Bayesian modeling
Bayesian modeling is being increasingly used in modern machine learning
research. The modeling task is to deﬁne a model and learn the unknown
parameters (or latent variables) using the observed data. The Bayesian
data analysis models the uncertainty observed in the true value of an un-
known parameter using a probability distribution. This principled means
of representing uncertainty is especially advantageous, when the data
samples are few and noisy. Therefore, the salient feature of the Bayesian
analysis is that when uncertainty exists, it learns a posterior distribution
specifying a range of values for the parameter, while taking into account
the prior information.
The posterior distribution of the parameter is deﬁned by the likeli-
hood and the prior. The likelihood function determines the impact of data
on the parameter while the prior probability distribution encodes any
prior information concerning the parameter. The Bayes theorem gives
this for parameter θ and data X as
P (θ|X) = P (X|θ)P (θ)
P (X)
,
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where the marginal P (X) is the normalization constant integrating the
posterior to one. The posterior probabilities P (θ|X) can be seen as like-
lihood P (X|θ) weighted by the prior P (θ), where the prior increases or
decreases the impact of likelihood in the posterior. In other words, the
modeling favors the solutions matching the prior. The prior may be used
to encode evidence or expert knowledge into the model. Moreover, it can
even assume a ‘non-informative’ setting, which enforces minimal assump-
tions so that the data can guide the posterior.
In this thesis, priors are used for inducing structure-revealing pat-
terns and regularizing the solutions by giving higher probability to sim-
pler representations. The regularization is especially beneﬁcial when the
sample count is low, and the level of noise is high.
2.5 Inference and Gibbs sampling
Once the model is speciﬁed, the learning task is to compute the poste-
rior distribution of the latent variables z and the parameters θ. However,
except for only the simplest models, there may not exist closed-form ana-
lytical solutions for the posterior evaluation [5]. In such cases, inference
of the parameters is performed via approximate schemes.
The approximate methods fall into two broad categories, determinis-
tic and sampling approaches [5]. The deterministic methods use analyt-
ical approximations of the posterior distribution. For example, they may
assume that the posterior factorizes into simpler distributions. Quite con-
trary, the sampling methods work by sampling from the joint posterior
and have the property that given inﬁnite computational resources they
can generate the exact result. Sampling methods are considered approx-
imate because only a ﬁnite number of samples can be obtained practi-
cally. The deterministic approaches such as the variational inference are
usually suitable for simple and smooth distributions, and are faster than
sampling methods. On the other hand, as sampling methods obtain the
samples from the actual posterior distribution, they are usually more suit-
able for complex distributions. Gibbs sampling is one of the most widely
used sampling algorithm and is described in the rest of this section. It
was used in Publications III, V and VI of this thesis.
Gibbs sampling is a widely applicable approximation algorithm [5].
It simulates observations as approximations of the joint posterior distri-
bution without directly sampling from the joint distribution itself. The
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method iterates the samples from the conditional posterior of each vari-
able while conditioned on the existing estimates of the remaining vari-
ables and the data,
zti ∼ p(zi|zt−1−i ,X, θ).
Here the latent variables z are split into k sub-parts z = (z1, z2, ...zk),
and t indicates the current iteration number of the sampler. In every
iteration, each of the k sub-parts is sampled sequentially based on the
latest updates of all other parts, improving the simulation at each step.
The algorithm is a Markov chain Monte Carlo (MCMC) method, where
successively sampling from the conditionals converges to the stationary
distribution, which, in this case, is the joint posterior distribution [57].
The samples from the stationary distribution can then be used to approx-
imate the joint posterior distribution, the marginal distribution of any of
the variables or for computing the expected values of the variables.
In practice, as the chain iterates towards convergence, the initial set
of samples prior to the stationary distribution are discarded as the burn
in. The samples from successive draws of the posterior may be strongly
correlated, in which case thinning may be used to break the dependence
by keeping only the every lth sample [57]. The zt=0 can be initialized in
several ways with sampling from the priors being a common choice. The
effect of this random initialization and the stochastic nature of the chains
can be partly mitigated by using multiple chains for averaging or selecting
a reliable one. Therefore, with its ease of formulation, Gibbs sampling is
a simple, reliable and a well studied standard choice.
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3. Biological responses to drugs
Cellular response to drugs depends on several factors including the mul-
titude of targets the drug can bind and the resulting pathways perturbed.
It is also well understood that there are potentially several pathways con-
nected with each cellular phenotype. This presents a many-to-many re-
lationship from drugs to targets and from pathways to responses, with
the majority of this information being unknown. Given this incomplete
knowledge, comprehensively modeling the drug responses over a diverse
drug library is a goal yet to be achieved. However, as drugs bind to the
targets yielding the effects, the binding is of central importance to the
response. This binding of the drug-target pair depends primarily on the
structural correspondence of the drug molecule and the binding cavity of
the target. Therefore, in principle, the responses to drugs can be modeled
comprehensively by learning a mapping between the structural properties
of the drugs and their responses, if done on a genome-wide scale.
In this chapter, the response measurements and structural properties
of the drugs used in the thesis are presented brieﬂy. Interested readers
are referred to more details and the Publications in each section.
3.1 Gene expression measurements
Cellular proteins are the functional blocks executing the mechanisms in
every cell. In order to learn the actions or reactions of the cells, it would
be ideal to measure the complete protein expression of the cells. However,
with the current state of the art, reliable and cost effective techniques
are not available and, therefore, approximate alternatives are commonly
used. The most widely used means of estimating the type of activity in
a cell is the expression of all the genes in a particular condition. These
patterns, referred to as gene expression, are well known for their ability
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to differentiate between the different types [58] and the behavior of cells
[59]. Studying the changes in gene expression has been valuable in un-
derstanding different medical conditions [60], disease processes [61], and
otherwise to explore the therapeutic applications of drugs [62]. For exam-
ple in cancers, it is valuable to identify the survival-related genes whose
expressions are altered by a drug [63].
Microarrays [64] are extensively used for measuring genome-wide gene
expressions. They measure the expression of thousands of short prede-
ﬁned sequences, which are then preprocessed to obtain gene-level activ-
ity. These measurements can be signiﬁcantly noisy [65], and require pre-
processing and corrections prior to their practical use [66]. More recently,
RNA sequencing has emerged as a technique with wider coverage for mea-
suring gene expression responses [67, 68]. However, this thesis focuses
on microarray gene expression data, due to the availability of large-scale
drug proﬁling data sets [3].
A common way of analyzing the processed gene expression data is dif-
ferential expression, where the expression of interest is compared with a
control signal. This procedure builds the notion of directional changes in
expression. For example, comparing post and pre-treatment expression
of genes can identify which genes have been up-regulated (increased in
expression) and which down-regulated, as a result of a treatment. Dif-
ferential expression is usually computed as fold-change, i.e., a log2-ratio
between treatment and control. In order to determine which genes have
been differentially expressed, standard statistical tests such as the t-test
are commonly used to test signiﬁcances [69]. A large number of genes
is usually tested for the signiﬁcance, and multiple hypothesis correction
needs to be carried out. For corrections, the standard methods are the
Bonferroni correction and the false discovery rate [70, 71]. With advance-
ments in machine learning, it has also become common to study differen-
tial gene expression values of several case-control samples directly with
computational methods, to test and identify different hypotheses [15, 72].
It is also informative to analyze expression changes in light of prior bi-
ological knowledge. In this line, Gene Set Enrichment Analysis [GSEA;
73] and Gene Ontology enrichments [GO; 74] of known biological path-
ways and processes have gained signiﬁcant success. In short, gene ex-
pression responses form a valuable genome-wide resource to study cellu-
lar responses, in particular, drug action mechanisms.
This thesis utilizes the drug-treatment responses from the Connec-
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Table 3.1. Data set usage in the publications of this thesis. The data sets are obtained
from the CMap and the NCI60 databases, and also the structural descriptors
of the drugs. The GSEA and Gene expression present two different represen-
tations of the CMap data. The toxicity data set from NCI60 and different types
of structural descriptors are described in Sections 3.2 and 3.3, respectively.
Data sets
Publication CMap NCI60 Structural descriptors
I GSEA VolSurf
II GSEA VolSurf
III Gene expression FCFP + Pentacle
IV VolSurf + Pentacle
V Gene expression Toxicity
VI Gene expression Toxicity FCFP
tivity Map database (CMap, [3]) that hosts microarray gene expression
responses of several cancer cell lines to over 1300 drugs. The CMap data-
base has been successfully used by the scientiﬁc community, for example,
to discover the mode of action of drugs [16] as well as new biological links
between multiple drugs [15]. The three major cell lines used in CMap,
HL60, MCF7, and PC3 come from three different cancers, namely blood,
breast and prostate cancers. Therefore, this data presents a unique view
of the genome-wide responses of cancers to drugs, over a set of 11,000
genes that are measured for each sample. The data set contains ∼7000
gene expression measurement samples including replicates. The mea-
surements come from three different microarray platforms, with over 85%
of the samples proﬁled with one of them, the Affymetrix HT-HGU133A
chip, and was therefore used in this thesis. The data set contains both
post and pre-treatment cellular responses of genes and is preprocessed to
obtain a treatment vs. control differential gene expression response for
each drug-cell pair (further details are given in Publication I). A positive
value in differential expression corresponds to up-regulation of the genes
while negative corresponds to down-regulation. Gene set summaries were
also computed as a dimensionality reduced representation of each sample
using GSEA (Publications I and II, Section 4.1). The CMap data set was
used in all publications of this thesis except Publication IV as enlisted in
Table 3.1.
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3.2 Drug sensitivity measurements
The drug sensitivity analysis aims to identify the concentration threshold
of a drug required for a particular pharmacological action. The process is
usually conducted by administering multiple different doses of a drug to
a cell and measuring the cell viability or inhibition, resulting in a dose-
response curve. The dose-response curves can then be used directly in
the analysis or summarized in one or more standardized values such as
the GI50 (growth inhibition of 50%). Drug proﬁling presents a phenotypic
view of a cell’s response to a drug, and can also be used to describe toxic
outcomes depending upon the application [75, 76]. The drug sensitivity
measurements have gained signiﬁcant attention in studying responses of
cancer cells, where a set of drugs are tested over a set of cell lines to
identify sensitive and resistance behaviors [77, 78].
Large scale drug proﬁling has led to the possibility of not only identi-
fying sensitivity or toxicity patterns of the drugs [79], but to also search
for genomic markers that may be indicative of the responses [80, 81]. Sev-
eral studies have recently been conducted to measure drug sensitivity of
human cancer cell lines against large collections of drugs, along with ge-
nomic proﬁling of the cells to identify potential biomarkers [78, 82]. On
a complementary front, drug treatment gene expression data has also re-
cently been shown as a better classiﬁer of drug toxicity than chemical
descriptors of the drugs [83].
The NCI60 is the largest panel of drug sensitivity data measured with
over 40,000 compounds tested on 60 different cancer cell lines [77]. The
data set has been used in several studies, for example to establish the
mechanisms of action of the compounds [84, 85] and to predict their cy-
totoxicity [75, 86]. In this thesis, dose-response summaries are obtained
from NCI60 for all the common drugs and cell lines that have correspond-
ing drug treatment gene expression measurements in CMap [3]. The
data set presents three response measures, the GI50 (growth inhibition of
50%), LC50 (50% lethal concentration) and TGI (total growth inhibition).
The measurements are then preprocessed to obtain a positive value if the
concentration of the drug used in the Connectivity Map was toxic (higher
than the dose-response values), and negative otherwise. The transformed
data set therefore represents concentration-dependent toxicity values and
has been used in Publications V and VI of the thesis (Table 3.1).
30
Biological responses to drugs
Figure 3.1. 2D Fingerprints of an example compound (digitoxigenin). Left: The 2D
structure of digitoxigenin is shown. Right: The 2D ﬁngerprints represent
the compound as structural fragments. In this example, Functional Connec-
tivity Fingerprints (FCFP4, Section 3.3.1) are used to compute the structural
fragments of digitoxigenin. A total of 34 fragments are found in digitoxigenin,
3 of which are shown here.
3.3 Structural descriptors
Structural descriptors of drugs represent each compound with a set of
features of its structure and function. Different types of 2D and 3D de-
scriptors exist, each optimized for different criteria [87]. The selection of
appropriate types of descriptors is important, especially in this work as
the aim is to represent drug molecules in a way that assists capturing
the biological functions. Some of the key descriptor types are elaborated
and reasoned in the rest of this section. One or more of these descriptor
sets are used in each publication of this thesis, except Publication V as
enumerated in Table 3.1.
3.3.1 2D ﬁngerprints
The 2-dimensional ﬁngerprints represent the structural and functional
properties of drugs by formulating the presence or absence of the frag-
ments, allowing easy visual inspection (Figure 3.1). MACCS ﬁngerprints
are one of the traditional examples of 2D ﬁngerprints that represent drugs
with a predeﬁned set of 166 structural fragments [88]. The Functional
Connectivity Fingerprints [FCFP; 89]) are an advanced formulation of
the 2D circular topological ﬁngerprints. They have been designed specif-
ically for modeling of structure-activity relationships and similarities be-
tween the drug, and, therefore, have been a descriptor of choice in such
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studies [90–92]. FCFP can represent variation in novel structures as they
compute the fragments dynamically, instead of using a predeﬁned set.
Therefore, FCFP can be used for identifying 2D substructures that make
novel compounds structurally similar and are responsible for biological
activity.
3.3.2 3D descriptors
Amongst a host of 3D descriptors, those based on molecular interaction
ﬁelds (MIFs) are well suited for structure-activity modeling and drug dis-
covery [93]. Instead of describing the molecules structural skeleton, these
MIFs take a complementary approach and sketch out the interaction po-
tential of a compound with a set of different probes. For a compound,
this could potentially be used to characterize interaction sites around the
molecule or summarize the different physicochemical, pharmacophoric,
and shape-based properties that are relevant for its pharmaceutical ap-
plication. When analyzing multiple compounds with MIFs, extracting the
relevant information, and the alignment of molecules have traditionally
been the major bottlenecks. However, recent advancements such as the
VolSurf and Pentacle have substantially overcome these.
VolSurf
The 3-dimensional VolSurf descriptors [94] are based on molecular inter-
action ﬁelds and are speciﬁcally designed for optimization of pharmacoki-
netic properties. Unlike the 2D ﬁngerprints, which represent the struc-
tural fragments, VolSurf describes the generic physicochemical properties
of the molecules. They are, therefore, capable of grouping together com-
pounds that have different chemical structure yet possess the same type
of chemical properties. VolSurf summarizes the interaction contours from
MIF by computing shape and volume-related statistics into a set of prede-
ﬁned descriptors. These include interactions such as lipophilic, lipophobic,
hydrophilic, and hydrophobic, resulting in a set of 76 structural features.
Pentacle
The Pentacle descriptors are advanced 3-dimensional ﬁeld distance de-
scriptors [95] that also use molecular interaction ﬁelds to capture the
functional properties. They encode the detailed interaction potential of
the compounds with the chemical probes, at dynamically computed mark-
ers. These interaction potentials represent the molecule (its charge and
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shape) as the target molecule would see it. Therefore, Pentacle descrip-
tors can group together compounds with different chemical structures, but
having similar interaction potential with a receptor. This characteristic is
important in the applications of this thesis, as it allows grouping together
compounds that bind into the same binding pocket despite structural dif-
ferences, which traditional ﬁngerprints are unable to recognize. In com-
parison to VolSurf, Pentacle descriptors are more detailed and describe
pharmacophore features extensively. The dimensionality of the resulting
Pentacle descriptors depends on the size of the molecules and is usually
much higher than VolSurf. Very recently, both VolSurf and Pentacle have
shown success in structure-activity analysis [96–98].
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4. Multi-view models for drug
responses
In modern chemical systems biology, the high-throughput proﬁling of a
compendium of compounds against genomically heterogeneous cancer cell
lines has unveiled diverse and interesting relationships between the re-
sponses. Several computational approaches have used massively high-
dimensional genome-wide responses to investigate the drug action mech-
anisms [12, 15, 16, 99]. On the other hand, various studies use the chem-
ical properties of the drugs to predict their univariate effects [97, 100]. To
combine these complementary approaches, this research formulates the
hypothesis that drug structure-response relationships can be studied on
the systems-wide level in a data-driven manner. Such systematic stud-
ies are valuable as they may ultimately assist in improving drug design
and personalizing treatments. Speciﬁcally, this chapter pursues machine
learning methods to model the relationships between structural descrip-
tors of drugs and their corresponding genome-wide responses, over multi-
ple types of cancer.
The ﬁrst aim here is to study the effects of chemical structure in the
context of multidimensional biological readouts, rather than to use a sin-
gle target ‘activity’ as in the conventional QSAR studies [13]. When the
goal is to search for relationships between two multivariate data sets in an
unbiased fashion, dependency modeling based approaches such as canon-
ical correlation analysis (CCA) match the objective directly. Section 4.1
uses canonical correlation analysis (CCA) on the largest genome-wide
drug proﬁling data resource (CMap, section 3.1) and a set of chemical
features, in search of correlated patterns (Publication I). The study for-
mulates the structure-response problem in a dependency modeling frame-
work and presents a systematic pipeline for analysis of the genome-wide
responses.
The results demonstrate that systematic dependency modeling suc-
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cessfully identiﬁes both known and novel insights; and also opens up
newer horizons to be explored. The study also suggested that multiple
diseases may produce response patterns that may be partly speciﬁc to
only one or few of the diseases (cancer types). Such response patterns, if
existing, may be discovered through multi-source modeling. Section 4.2
presents a novel multi-view model, and applies in collaboration to explore
patterns between drug structures and their responses over multiple dis-
eases (Publications II and III). The results illustrate the advantages of the
improved methodology. Finally, multi-source modeling is also evaluated
for prediction of drug targets in section 4.3 (Publication IV).
4.1 Canonical correlation analysis for drug responses
The structure-response relationships can be learned comprehensively by
searching for links between drug structures and their genome-wide re-
sponses. This translates to the machine learning task of identifying la-
tent interactions between multivariate structural descriptors of drugs and
their corresponding multivariate (genome-wide) responses. Publication I
proposes a data-driven solution to model the hidden interactions in a sys-
tematic manner. The interactions are hypothesized to describe the un-
derlying biological processes, and are identiﬁed by discovering the joint
low-dimensional subspace that relates drug structures with cellular re-
sponses.
The analysis is based on the differential gene expression response
of 1159 drugs originating from the Connectivity Map database [3] (sec-
tion 3.1). In order to reduce the dimensionality of this gene expression
data and to bring in prior knowledge of known biological responses, Gene
Set Enrichment Analysis (GSEA) [73] was performed. For GSEA, the cu-
rated gene sets (C2) from the Molecular Signatures Database1 [73] were
selected for enrichment, as they are both carefully curated and cover over
90% of the genes in this data. These include gene sets from online path-
way databases and knowledge of domain experts. A few example gene sets
are theHSA05221_acute_myeloid_leukemia (AML) that lists known genes
involved in AML, ET743_Sarcoma_up enumerates genes up-regulated in
sarcoma’s as a result of treatment with Trabectedin (an anti-cancer drug),
and the Oxiadative_Phosphorylation which is a metabolic pathway. The
GSEA summarizes the gene-level expression into a gene set activation
1http://www.broadinstitute.org/gsea/msigdb/collections.jsp
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proﬁle. As a result, the 11,327 genes from CMap were summarized into
1321 gene sets. On the other hand, the chemical space of the 1159 drugs
was represented by the 3D VolSurf descriptors (section 3.3.2). VolSurf
comprises of 76 descriptors that are capable of grouping together com-
pounds having the same type of chemical properties despite having differ-
ent chemical structures.
4.1.1 Dependency modeling via canonical correlations
For discovering relationships in a data-driven way, the computational
task is to model the dependencies between the two data sets (structural
descriptors and gene set responses) in a comprehensive fashion. CCA,
ﬁtting the goal directly, discovers a joint low-dimensional representation
that splits the two input spaces (chemical and biological) into distinct com-
ponents. Each of the components statistically correlates the patterns of
one space (chemical descriptors) with those of the other space (biologi-
cal response). As drugs generate diverse effects, component-based models
are suitable for segregating the multiple different responses. Therefore,
with CCA, the joint decomposition of the structure-response data sets re-
sults into correlated components, which are hypothesized to describe the
underlying biological phenomena driving cancer drug response. The key
assumption here is that if there is any statistical dependency between the
patterns in the chemical space and the biological responses, these pat-
terns are then informative for developing hypotheses about the mecha-
nisms of drug actions.
Methodologically, CCA is an established data integration approach
that maximally explains the dependency between two data sets [8]. The
method linearly projects the data sets to obtain a maximally correlated
low-dimensional representation. This low-dimensional representation aka
the shared space or the components capture the statistically shared pat-
terns between the two data sets, whereas patterns speciﬁc to any one of
the data set are considered noise and ignored. This split matches exactly
to the assumption that shared structure-response patterns are of prime
interest.
Analogous to most genomics data sets, the CMap gene set proﬁles
have more dimensions than the number of samples with several highly
correlated variables. In such a situation, there is a potential for the CCA
covariance matrices to become ill-conditioned, which could result in nu-
merical inaccuracies while computing the inverse. This is a classical prob-
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lem when D > N , and regularized solutions are available [101–103].
Given two data sets X ∈ RN×D1 and Y ∈ RN×D2 , with N paired
occurrences of samples in the two views, regularized CCA ﬁnds K linear
projections2 of the data sets, Xwk and Yvk, such that their correlation Pk
is maximized as,
Pk = argmax
wk,vk
cor(Xwk,Yvk) (4.1)
= argmax
wk,vk
wTkCxyvk√
wTkCxxwk + L1‖wk‖2.
√
vTkCyyvk + L2‖vk‖2
.
The vectors wk and vk are the projection weights, or loadings when nor-
malized, while the projected space of data sets Xwk and Yvk constitutes
the CCA components or canonical covariates, capturing the shared pat-
terns between the two data sets. The ﬁrst component k = 1 is found
such that the correlation Pk is the largest possible. All other compo-
nents k = 2, 3... are computed analogously, but with the additional con-
straint that they are uncorrelated with the previously obtained compo-
nents. These constraints ensure that the ﬁrst K components capture the
strongest shared effects, which are also distinct from each other. The reg-
ularization replaces the empirical covariances Cxx and Cyy by their reg-
ularized estimates Cxx + L1I and Cyy + L2I, and also acts as a penalizer
on the projection weights L1‖wk‖2, L2‖vk‖2, preferring a simpler solution.
Once found, the CCA components decomposing the data sets (struc-
tural descriptors and gene set responses) into components are represented
by the sum of the projections Z = Xwk +Yvk. The most prominent sam-
ples (drugs) that represent the component are those having the largest
values in |Z|. The positive and negative scores can be thought to repre-
sent two distinct sets of samples (drugs) that present opposing behaviors
and should be analyzed separately. The canonical loadings with high cor-
relation values identify the most important structural features in a com-
ponent that share the patterns with corresponding gene set responses.
Therefore, a CCA component k can be represented by a set of samples
(drugs) that have speciﬁc features (structural properties) activating the
biological response in particular gene sets.
2In Publication I the symbol S was used to denote components, while K in all
the rest. In the interest of consistency, K is used throughout the thesis.
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4.1.2 Drug structure-response relationships
To validate if the structure-response relationships could be modeled with
CCA, the discovered components were subjected to quantitative and qual-
itative validations. Quantitative validation was done by evaluating the
model’s ability to retrieve similar drugs when queried with a single drug.
The retrieval performance was measured as the mean average precision of
retrieving similar compounds, with similarity measured over an indepen-
dent drug-protein target data set compiled from several publicly available
databases. To test the model for its ability to extract relevant information,
the retrieval experiment was performed on both the integrated data space
and the individual biological or chemical data spaces separately. The re-
sults conﬁrmed that the integrated space is more informative of drug re-
sponse than any of the data sets separately, verifying that the CCA com-
ponents extracted biologically meaningful signals from the data. In this
respect, the conclusions of this work can also be useful as a means of
better characterizing the drug molecules based on joint modeling of their
structure and response proﬁles.
For qualitative validation and exploration of the novel links, the learned
model parameters were studied with novel visualization schemes and gene
ontology enrichments for interpretations. The resulting interpretations
and visualizations brought out new links of interest to biologists, as brieﬂy
summarized next.
The top 10 components having signiﬁcant correlations were examined
for detailed interpretation and are presented in Publication I, while an
overview and most signiﬁcant ﬁndings are elaborated here. Here each
component represented the relationships between structural features and
biological responses that were triggered by a set of drugs (as described
in sec 4.1.1). The key drugs in each component were analyzed for the
common mechanisms and the drug classes to which they belong, reveal-
ing several known drug groups such as HDAC inhibitors, cardiac glyco-
sides, and protein synthesis inhibitors, being enriched in the components.
The biological action captured by each component was identiﬁed using
the most strongly correlated gene sets. In several components, the bio-
logical response was recognized as the known effects of the drug groups
conﬁrming them to be in line with established biological knowledge. The
strongly correlated chemical features in each component were found to be
representing particular VolSurf properties that were linked, by the mo-
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del, to the biological response. In summary, the components were veriﬁed
to represent well-established ﬁndings while revealing novel relationships
between the structural properties and the biological responses.
Several of these 10 components also discovered novel and interest-
ing responses. For example, components 2B and 10A both were found to
represent two separate aspects of DNA damage response, connected to
two separate molecular features, potentially indicative of different mech-
anisms. The key drugs of these two components were then examined for
toxic indications using the NCI60 database [77], conﬁrming that most of
them had been administered at the toxic doses in CMap.
Component 3A also revealed a potentially interesting response, relat-
ing to mitochondrial and metabolic stress related processes. The compo-
nent was therefore further investigated for functional transitions caused
by drug responses. To this end, a non-linear dimensionality reduction
tool called Neighbor Retrieval Visualizer [NeRV; 104, 105] was used. The
visualization using NeRV mapped the component non-linearly onto a 2-
dimensional display of the reference states, such that similarities were
preserved as faithfully as possible. The reference states were represented
using 30 independent and untreated breast cancer cell lines denoting dif-
ferent molecular subtypes. Interestingly, the NeRV-visualization of the
component (3A) revealed that the captured response of DNA-damaging
drugs made the cells resemble therapy-resistant cancer cell lines. This
transition indicates that the regulation of these metabolic genes was po-
tentially a protective or resistance-mediating response.
Since there is emerging interest in the involvement of metabolism in
cancer and drug resistance [106–108], the expression of component 3A
genes was further explored for its therapeutic relevance. To this end,
initial wet lab experiments were followed up in collaboration, which in-
dicated that siRNA-mediated silencing of 14 of these genes (including
metabolic genes such as HADHA, IDH3B, ME2, PDAP1 and UQCRC1)
did result in chemosensitization of cells to the used DNA damaging agents
[109], giving conﬁdence to the discovered hypothesis.
To sum up, decomposing structure-response interactions on a genome-
wide scale can be solved via dependency modeling methods such as CCA,
generating hypothesis for unexplored polypharmacology. The approach
is ﬂexible and can be extended to model dependencies from other types
of chemical descriptors and genome-wide biological responses. However,
there were limitations of the study. The study was constrained to a limited
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set of descriptors and the dimensionality-reduced GSEA proﬁles. Though
the analysis indicated that the use of GSEA was not detrimental to the
performance of the method, gene interpretability would become easier
by directly using gene-level data in the modeling process. The more de-
tailed gene-level data and chemical descriptors were incorporated in sec-
tion 4.2.2, by using a Bayesian solution that can better handle uncertainty
when the data dimensionality is high.
4.2 Group factor analysis for drug responses
The cellular responses to a drug are complex in nature and depend on
a multitude of characteristics. One of the most important aspects is the
type of the cancer. Specially, different cancers are heterogeneous in nature
and respond selectively to the drugs. This selectiveness makes it valuable
to learn which of the responses are speciﬁc to a cancer type and which
common across several of them. This section extends the challenge of
structure-response modeling to multiple different diseases (cancer types)
and addresses the question: Can systematic modeling distinguish between
structurally driven responses common to multiple cancers from those spe-
ciﬁc to one or few. First, in section 4.2.1 a targeted study designed for
structure-response relationships over multiple cancers is presented, with
a new multi-source dependency modeling method called Group Factor
Analysis (Publication II). The study conﬁrms the hypothesis that model-
ing dependencies between multiple-cancer responses from more than two
paired data sets (also known as ‘views’ ) via multi-view models is feasi-
ble and promising. An extension of the method for high-dimensional data
is then presented, and a detailed analysis of the multi-structure multi-
cancer response is followed (section 4.2.2, Publication III).
4.2.1 Dependency modeling via group factor analysis
The dependency modeling task now becomes the identiﬁcation of com-
mon patterns from multiple paired data sets, as the problem extends to
responses of multiple types of cancers. Existing multi-set extensions of
CCA formulate the task for more than two data sets [110, 111]; however,
they only model components common to all views, and hence are unable
to identify patterns shared by only a subset of the views. Publication II
presents a novel latent component model Group Factor Analysis (GFA)
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that not only extracts the statistical dependencies between all the data
sets but also identiﬁes dependencies between any subset of them.
Group Factor Analysis (GFA) is a model designed to capture relation-
ships (statistical dependencies) by reducing the collection of data sets
(views) into a combined set of low-dimensional factors (components). A
component can be active in one or more of the data views, representing
that it captures the underlying relationships between the corresponding
views only. For example, a component active in all the views captures
the shared dependency structure between all the views while one active
in a single view identiﬁes variation and features speciﬁc to that particu-
lar view only. GFA learns the activity of the components in a data-driven
manner making it possible to identify dependencies that exist between
a subset of the views. In the structure-response decomposition problem,
each of the factors can be thought to represent a distinct underlying bio-
logical process that has generated parts of one or more of the data sets.
Therefore, the task of GFA here is to factorize the collection of structures
and multiple responses while separating the components capturing the
structure-biology relationships from the rest.
Formally, given a collection of M data setsX(1),X(2), ...X(M) ∈ RN×Dm ,
having N paired samples (drugs), and a separate set of dimensions Dm
in each view, GFA searches for a K-dimensional matrix factorization for
the entire collection. The model is formulated in a Bayesian setting as a
product of a Gaussian latent component matrix Z ∈ RN×K containing the
K components, and a projection weight matrix W(m) ∈ RDm×K for each
data set m. The model is represented as
x(m)n ∼ N
(
W(m)zn, I(τ
(m))−1
)
zn ∼ N (0, I)
w
(m)
:,k ∼ N
(
0, (α
(m)
k )
−1
)
(4.2)
α
(m)
k ∼ Gamma(aα, bα)
τ (m) ∼ Gamma(aτ , bτ ) ,
where τ (m) denotes the view-speciﬁc noise precision. The latent variables
zn are common between all the views, representing the response patterns.
GFA solves the joint decomposition problem using the group-wise sparse
matrix factorization of all data sets, where each data set is considered a
group. The group-wise projections W(m) capture both group-speciﬁc vari-
ation (activity seen exclusively in one view), and dependencies between
the groups (activity in more than one views). This is achieved by model-
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ing the total variation in the data while constrained by the group-sparse
prior. The group-sparse prior (via α(m)k ) controls the scale of the projec-
tion weights w(m):,k for each of the component-view pairs. Higher values
of α(m)k shrink the corresponding w
(m)
:,k towards zero switching the compo-
nent off, while smaller values of α(m)k increase the scale of w
(m)
:,k , making
the component active in the view. GFA learns the α(m)k in a data-driven
way, yielding dependency patterns between the views. As a practical step,
α
(m)
k is thresholded with respect to the captured variance to obtain active
and non-active status of the components.
GFA is applied on the four co-occurring data sets of the chemical sys-
tems biology problem. The chemical space is represented by the 3D Vol-
Surf descriptors as in section 4.1; however, the biological space is repre-
sented by three views, formed by gene set activation proﬁles of the three
different cancer types [CMap; 3]. The application goal here is to dis-
cover factors that describe interesting statistical dependencies between
the views. The exact question is: Does there exist any relationship between
drug structures and their biological responses, and can we differentiate be-
tween responses that are disease-speciﬁc from those which are generic to all
three subtypes of cancer.
To validate if multi-source structure existed and was captured by the
model the component activity of GFA was examined. The activities re-
vealed that indeed the model discovered several components shared be-
tween descriptors and biological responses. Components of both types
were found: (i) components shared by chemical structures and a few of
the cell lines giving hypotheses for speciﬁc cancer variants, and (ii) com-
ponents shared by chemical structures and all of the cell lines constitut-
ing responses common to all cancer subtypes. The ﬁrst components of
both types were examined by collaborators and found in accordance with
established biological knowledge.
To validate the model quantitatively, for the task of discovering bio-
logically meaningful components, its ability to retrieve similar drugs was
evaluated on an independent drug-target data set. The mean average pre-
cision of retrieving the drugs having similar known targets was found to
be signiﬁcantly higher for the integrated component space of the model,
than the chemical descriptors and the three gene set proﬁle spaces sepa-
rately. The result conﬁrms that the model extracted biologically meaning-
ful information.
Given the heterogeneity of available high-throughput biological data,
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the application though limited in its interpretation did demonstrate the
model to be useful in identifying relevant and biologically meaningful
components. The subsequent section extends the model with sparsity
priors and presents a detailed structure-response analysis using genome-
wide gene expression proﬁles of the three cancer types, when coupled with
multiple detailed and extensive sets of structural descriptors.
4.2.2 Bayesian sparse group factor analysis
With plausible results in section 4.2.1, an extended model is now proposed
for the massively high-dimensional data while simultaneously increasing
the interpretability of the components by enforcing sparse priors. The ex-
tended model is applied to the genome-wide screening assay data of three
cancers from CMap and two sets of advanced chemical descriptors, to in-
vestigate the cancer-speciﬁc and across-cancer effects of drug structures.
The gene-level expression data of 11,327 genes is incorporated directly
into the model, instead of the 1321 gene set responses (used in section 4.1
and 4.2.1). This detailed information makes it possible to link the struc-
tural features directly to the activity of the genes and is expected to make
components easier to interpret. Additionally, the advanced structural fea-
tures may extract novel as well as known links of interest.
The formulation of GFA in eqn. 4.2 uses a group-wise sparse prior
for determining the view activity. The speciﬁcation is sparse at the level
of data sets but dense at the level of individual features. Feature-level
sparsity can better regularize the solution while also aiding easier in-
terpretability. The introduction of feature-level sparsity in the model is
non-trivial since the model is already group-wise sparse. This is over-
come by introducing layered sparsity: group-level sparsity followed by a
sub-layer of feature-level sparsity. The group sparsity (view activation)
is now encoded by formulating a group spike and slab prior [112], and is
represented by binary variables that control the activity of the kth compo-
nent for group m. The second layer of sparsity is encoded on the features
within a group via an element-wise automatic relevance determination
prior [ARD; 113]. The ARD enforced on the projection weight matrices
pushes individual weight values of irrelevant variables towards zero, in-
ducing each of the active components to become feature-wise sparse. For-
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mally, the sparse GFA model is represented as
x(m)n ∼ N
(
W(m)zn, I(τ
(m))−1
)
zn ∼ N (0, I)
w
(m)
d,k ∼ h(m)k N
(
0, (α
(m)
d,k )
−1
)
+ (1− h(m)k )δ0 (4.3)
h
(m)
k ∼ Bernoulli(πk)
πk ∼ Beta(aπ, bπ)
α
(m)
d,k ∼ Gamma(aα, bα)
τ (m) ∼ Gamma(aτ , bτ ) ,
where the h(m)k are binary variables controlling group sparsity. For the
view-component pair shut down by the binary variables (h(m)k =0), the delta
function δ0 forces zero on all the corresponding weights w
(m)
:,k . Whereas
for the active view-component pairs (h(m)k =1), the weights are sampled
from the element-wise ARD α(m)d,k that brings in the second layer of spar-
sity, but for each of the d features. This formulation allows both the
entire components as well as features within active components, to be
switched off. A Gibbs sampler was implemented to perform model infer-
ence, and an open source implementation of sparse GFA is provided at
http://research.ics.aalto.fi/mi/software/GFAsparse.
GFA decomposes the data sets into components that are shared be-
tween one, more, or all of the views. This decomposition results in sev-
eral exciting possibilities of view-shared components. First, the compo-
nents shared between chemical and all biological views hypothesize for
the structurally driven responses that are common across all of the an-
alyzed cancer-types. Second, the components that are shared between
chemical and one (or few) of the biological views present cancer-speciﬁc
hypotheses. Finally, the remaining components that are speciﬁc to the bi-
ological views or the chemistry views do not represent structure-response
relationships.
A component k active in at least one chemical and one biological view
encodes the cross-space relationships and can be analyzed as follows. The
weight vector w(m):,k represents the contribution of each feature into the k
th
component for identifying the linked descriptors and genes. The descriptor-
gene relationships are observed prominently in the most signiﬁcant drugs
of the component characterized by the highest magnitude scores of z:,k.
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4.2.3 Multi-response relationships
The multi-response relationships between responses of multiple cancer
types and multiple structural descriptors is now studied with sparse group
factor analysis. Speciﬁcally, the multi-cancer relationships are explored
between the gene expression responses of three different cancers and two
sets of advanced structural descriptors. The two types of advanced struc-
tural descriptors are the 3D Pentacle and the detailed though more tra-
ditional functional connectivity ﬁngerprints FCFP. The Pentacle can cap-
ture molecular ﬁeld similarities between drugs corresponding to potential
biological functional similarity despite the drugs being structurally dif-
ferent (section 3.3.2). The FCFP are more traditionally used ﬁngerprints
for structure-response analysis and capture similarity between drugs that
can be directly related to presence or absence of structural fragments (sec-
tion 3.3.1). While FCFP provide a direct mechanism of identifying links
between structural fragments and response, the Pentacle adds in the po-
tential for novel drug associations. For the biological response, the 11,327
treatment vs. control differential gene expression responses of the three
different cancer cell lines are used as three separate data views. The
gene expression data coming from the Connectivity Map is obtained over
the common set of 682 drugs that were proﬁled on all the three cancer
cell lines. GFA run on the M = 5 data sets with K = 80, discovers 11
components of interest, i.e. shared between one or more structural de-
scriptors and one or more biological responses. These components form
hypotheses for structure-driven responses of drugs indicative for both the
cancer-speciﬁc variants and those common across all subtypes of cancer.
To validate the model’s informativeness, it was quantitatively evalu-
ated for discovering biologically and chemically meaningful components.
This was done by studying the components against the Chemical Entities
of Biological Interest Ontology [ChEBI; 114]. The ChEBI is currently the
largest curated ontology of small molecule drugs that classiﬁes the com-
pounds with respect to their chemical structure, biological roles they are
known to play, and their applications.
The GFA components shared between chemical and biological views
were, therefore, hypothesized to be in line with the known relationships
encoded in ChEBI. To test this, the similarity of top compounds from the
components was computed, as indicated by ChEBI regarding their struc-
tural and functional relationships (data external to the model). This is
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compared to the corresponding similarities from (i) random choice of com-
pounds, (ii) drug clusters learned for elicitation of action mechanisms us-
ing the CMap biological response data by [15], and (iii) structure-response
components of Publication I.
The result clearly showed that the shared GFA components signif-
icantly outperformed the random baseline, concluding that the compo-
nents were strongly in line with the known structure-role relationships
of ChEBI. Additionally, the GFA based components fared much better
than both of the comparison approaches endorsing the advantage of the
method.
All the 11 shared components were also qualitatively explored seek-
ing structural and functional similarities. Each component was hypoth-
esized to describe an underlying process that explained the relationships
between chemical descriptors and biological responses. The analysis iden-
tiﬁed three major results, as described next.
First, the components shared between the FCFP4 descriptors and one
or more cell lines identiﬁed the core 2D structural groups that were linked
with the response, creating a structure-response map. As key examples,
these included (i) the common Steroid Backbone of all the Cardenolides in
Component 1 that is linked to the DNA Damage Response of the drugs,
at the high concentrations at which the drugs were administered; and
(ii) the well known aromatic ring of the HDAC inhibitors in Component 2
was linked with the corresponding inhibition response of the drugs. These
structure-response relationships demonstrate that the methodology cor-
rectly identiﬁes the structural groups responsible for gene-level response
and, therefore, can be used as a principled tool for unsupervised explo-
ration and mining of structure-response relationships.
Second, 3 out of the 11 components showed cancer-speciﬁc responses,
entirely missed by the key earlier studies Publication I and [15]. The most
salient one was the leukemia-speciﬁc response of corticosteroids, which
indicated that the drug targets may be selectively active in leukemia
cells. The same component also revealed that simvastatin and repaglin-
ide, which are two structurally very dissimilar drugs, shared the same re-
sponse pattern of corticosteroids. This is an important ﬁnding with poten-
tial therapeutic implications in the light that recently lovastatin, which
is a close structural analog of simvastatin, was shown to have anti-cancer
activity in leukemic stem cells [115].
Third, the use of advanced Pentacle descriptors with the structure-
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response linking capability of GFA, allowed discovery of novel drug asso-
ciations. Though several examples are presented in Publication III, the
most prominent one is that of the 15 Delta Prostaglandin J2’s (PGJ2)
role as an HSP90 inhibitor drug. HSP90 inhibitors are well known for
anti-cancer activity, and their mechanism of action is also well-understood
[116]. PGJ2 and its analogs have also been studied for their anti-cancer
activity though their mechanisms of action have not been revealed ear-
lier. The analysis suggests that PGJ2 and HSP90 inhibitors despite be-
ing structurally very dissimilar, share speciﬁc Pentacle ﬁeld properties
that are linked in HSP90 inhibitor Geldanamycin to its binding with the
HSP90 protein. This chemical similarity coupled with a similar response
to the drugs on HSP related genes gives an indication that the PGJ2 may
be targeting HSP90. PubChem drug-target data reveals that PGJ2-HSP
pair falls in untested/unknown category as of yet, though the novel anal-
ysis is indicating a partly common mechanism of action.
The results demonstrate that GFA can discover meaningful relation-
ships between compounds and cell line expression that were not found
using simpler methods. Speciﬁcally, with multi-source modeling, it was
successfully possible to separate responses common to cancer subtypes
from those speciﬁc to a cancer variant. The model found both known
and novel structure-response links, leading to potentially valuable drug
indications. The quantitative validation conﬁrmed that the analysis is
well in line with the established structure-biology links. In summary, the
practical applicability of GFA is demonstrated to analyze the relation-
ships between differential gene expression data and structural properties
of drugs. This is an important problem because a successful method of
understanding the dependencies between the structures and responses
of speciﬁc diseases would enable additional optimization efforts for drug
designs and precision medicine.
4.3 Multi-source prediction of targets
The previous two sections discussed modeling the relationships between
structural properties of drugs and their biological function represented
by gene expression responses. The drug-target binding was not explicitly
modeled due to massively missing amounts of information. To explore the
potential of multi-source modeling in predicting the targets of drugs, a
study is carried out and presented next (Publication IV). The task is mod-
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eled as factorization of the drug-target matrix aided with side information
of the drugs (multiple types of structural descriptors) to better predict the
interactions. The analysis demonstrates that integrating multiple data
sets (as side information sources) improves the predictions.
4.3.1 Kernelized Bayesian matrix factorization
Publication IV presents Kernelized Bayesian Matrix Factorization (KBMF)
algorithm for factorizing a matrix by leveraging additional information
from side data-sources. KBMF performs the low-dimensional factoriza-
tion, such that the factors are learned using multiple side data-sources
in a non-linear fashion. To capture the non-linear effects, the side data
sets are encoded using Kernels, and their low-dimensional projections are
combined via Multiple Kernel Learning (MKL). Therefore, KBMF learns
the factorization using a weighted combination of the multiple side data
sets while learning the weights in a data-driven fashion.
4.3.2 Multi-structure prediction
The drug-target predictions were studied using multiple structural de-
scriptors of the drugs and the drug-protein interaction network data from
[117]. The data set comprises target information of 800 proteins over 855
drugs, with 4659 experimentally validated interactions. The side infor-
mation for drugs is represented by two types of structural descriptors, the
VolSurf and the Pentacle (also called Amanda).
The task of KBMF then is to use the multi-view structural proper-
ties of the drugs and predict the missing interactions in the drug-target
matrix. To model the non-linear relationships, Gaussian Kernels were
computed on both data sets representing them as side information Ker-
nels. KBMF employs MKL to utilize the two descriptor data sets simul-
taneously, for learning the drug-target interactions. The model is ﬁrst
validated for predicting the interactions in comparison to existing non-
Bayesian alternatives as measured by the AUC (area under the ROC
curve). The experiment is performed in a cross-validation setting while
varying the number of components and conﬁrms that KBMF outperforms
the comparison methods.
Having conﬁdence that the model outperforms the existing state of
the art, the particular multi-source hypothesis was tested. Therefore,
to determine the beneﬁt gained by the weighted combination of multi-
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ple side data sets, the model was compared to the cases, (i) when a single
side data set is used, or (ii) both the side data sets are concatenated in a
single view. The results conﬁrm that the principled handling of multiple
views via weighted combination of MKL results in the best prediction per-
formance (AUC), validating the hypothesis that multi-source models can
be used to predict drug-target interactions better. Very recently, a closely
related multi-source multi-task variant of KBMF has been used to pre-
dict drug responses, outperforming 40 other methods in the crowdsourced
NCI-Dream drug sensitivity challenge [118].
The model’s ability to retrieve similar drugs is also explored. Specif-
ically, the use of multiple side data sets is evaluated for its prospects in
retrieving similar drugs. Here the hypothesis is that the subspace useful
for prediction of drug-target interactions could be valuable for drug clas-
siﬁcations as well. The performance is measured as the mean average
precision of retrieving similar drugs when evaluated over an independent
validation data set. Speciﬁcally, the therapeutic classiﬁcation of drugs are
used as an independent validation data set, to measure the drug similar-
ity. The retrieval performance of the model with multiple descriptors com-
bined via MKL is compared to the performance of each descriptor individ-
ually as well as when concatenated in a single view. The results validate
that the drug-target prediction space supplemented with the multi-view
descriptors outperforms the alternatives. The ﬁnding implies that KBMF
can also be used as a metric learning method for drug similarities.
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5. Multi-tensor factorizations for drug
responses
When data sets are measured over multiple variables of interest, the un-
derlying structure may present multi-way relationships. In such cases,
tensor methods can preserve the natural structure in the data, and obtain
more compact and accurate representations in an efﬁcient way. Tensor
factorizations have recently gained much interest in the machine learn-
ing community to address some of the challenges posed by multi-way data
sets [43, 44, 119]. With heterogeneous and partially paired multi-way
data sets emerging, it is of prime importance to have integrative ten-
sor methods that can jointly factorize several tensorial data sets. As a
key application problem, different types of biological response measure-
ments under multiple experimental conditions require multi-way meth-
ods to study the underlying structure appropriately. This chapter aims to
contribute to this growing area of research by proposing the ﬁrst Bayesian
multi-source tensor factorization methods.
In the following, novel tensor integration methods are introduced.
Section 5.1 presents a Bayesian multi-view tensor factorization method
that ﬁnds a combined low-dimensional representation of multiple paired
tensors (Publication V). The method is applied as the ﬁrst Bayesian ten-
sor canonical correlation analysis to a novel toxicogenomics application
of integrating drug-disease responses. Section 5.2 extends the formula-
tion to allow coupled matrices and tensors, coining Multi-tensor factor-
ization (Publication VI). Finally, the methods are demonstrated in use
for both interpretability of underlying processes and predictions, on an
extended formulation of the drug-response decomposition problem (sec-
tion 5.3). The novel application sits at the juncture of toxicity, chemistry
and bioinformatics; and serves as an example of the novel formulations
that can be solved with the new multi-source multi-mode factorization
methods. Nevertheless, the new methods developed in this chapter are
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generic and applicable in any ﬁeld of science. For notational simplicity,
the case of third-order tensors is presented.
5.1 Bayesian multi-view tensor factorization
A novel model coined Bayesian multi-view tensor factorization (BMTF) is
presented that jointly factorizes multiple co-occurring tensors into a low-
dimensional and interpretable representation. Speciﬁcally, a novel multi-
view tensor factorization problem is formulated, and a Bayesian model is
presented as a solution. The multi-view tensor factorization problem is
introduced as joint factorization of paired tensors to learn a concise set
of multi-way factors determining the dependencies between the data sets,
in a data-driven fashion. This unique formulation poses three essential
modeling choices to be made, as discussed next.
First, the multi-way nature of tensors allows them to be factorized in
several different forms. The most widely used factorization approaches
such as the CANDECOMP/PARAFAC (CP) and the Tucker model family
were discussed in section 2.3. The CP factorization decomposes a tensor
as a sum of rank-1 tensors and has the advantage of being readily inter-
pretable similar to matrix factor analysis. It is based on the principle of
parallel proportional proﬁles [39], which allows the intrinsic axes to be
discovered automatically, providing unique solutions under mild assump-
tions [31, 40]. These properties make CP a valuable choice for BMTF.
The CP decomposes a tensor X ∈ RN×D×L into three constituent loading
matrices Z ∈ RN×K , W ∈ RD×K , U ∈ RL×K . Therefore, the joint CP
factorization of multiple paired tensors can be formulated by assuming at
least one of the loading matrices (for example Z) to be common across all
the tensors. The joint loading matrix makes it possible to capture depen-
dencies between the data sets.
Second, the joint factorization can be formulated considering the ten-
sor structure from two different perspectives. First, a tensor can consist
of a vector of samples, where each sample has two set of dimensions (i.e.
a matrix), forming a three-way tensor. This construction is analogous to a
set of slabs placed on top of each other where each slab is a single sample.
In a multi-view case, as both dimensions of each view could be different,
this setting corresponds to pairing between the views in the single sam-
ple mode as done by [120] for a non-probabilistic version of tensor CCA.
Alternatively, a tensor may be made up of a matrix of samples where each
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sample is a vector, forming a three-way tensor. This case is more similar
to the traditional matrix case, where the samples are vectorial in nature
(analogous to a ﬁber), with the difference that samples now come from
multiple covariates. In multi-view case, this corresponds to pairing in the
two sample modes of the tensor. While none of the existing tensor CCA
methods formulate the problem in the later fashion, it corresponds well
to the natural extension of most problems (including biological) that are
currently being analyzed via matrix methods. In BMTF, the pairing in
two modes is achieved by assuming the loadings in U and Z to be common
across all the tensors.
Third, the factorization should contain components that can be shared
by any subset of the tensors, i.e. one, some, or all the tensors. This gener-
alization is necessary to learn all the possible dependencies between the
views, as well as to differentiate amongst dependencies that exist between
two or more views from those speciﬁc to only one. This ﬂexibility can be
achieved by modeling the total variation in the tensors, such that a set of
view-speciﬁc loadings W(m) control which of the patterns from Z and U
are active in each view. Patterns active in more than one view are shared
between the views while those active in only one are speciﬁc to it. BMTF
enforces group-sparsity on W(m) making it possible to learn the exact na-
ture and sharing of the factors automatically from the data. In addition,
BMTF can determine the total number of components that represent each
view, as well as the entire collection.
Formally, the BMTF model for multiple (m = 1 : M ) paired tensors
X (m) ∈ RN×L×D(m) is formulated, to learn a low-dimensional (K) repre-
sentation explaining the entire collection. Assuming normal distributions
53
Multi-tensor factorizations for drug responses
and conjugate priors, the Bayesian model is constructed1 as
x
(m)
n,l ∼ N
(
W(m)(zn ∗ ul), I(τ (m))−1
)
zn ∼ N (0, I)
ul,k ∼ N
(
0, (βl,k)
−1)
w
(m)
d,k ∼ h(m)k N
(
0, (α
(m)
d,k )
−1
)
+ (1− h(m)k )δ0
h
(m)
k ∼ Bernoulli(πk)
πk ∼ Beta(aπ, bπ)
βl,k ∼ Gamma(aβ , bβ)
α
(m)
d,k ∼ Gamma(aα, bα)
τ (m) ∼ Gamma(aτ , bτ ) .
The latent variables Z and U are common to all the tensors and capture
the underlying patterns while the W(m) translate the patterns for each
tensor. A two layered sparsity formulation is used to learn the required
structure. The ﬁrst, group-sparsity controls the component-view activa-
tion via binary variables h(m)k inducing a spike and slab prior [112]. The
h
(m)
k is automatically learned from the data, such that a value of h
(m)
k = 1
corresponds to the component being active (w(m):,k ∈ R1×Dm) while h(m)k = 0
means not-active (w(m):,k ∈ 01×Dm). As an example, a component active in
two views has h(m)k = 1 for the corresponding two views, while h
(m)
k = 0
for the rest. Therefore, h(m)k learns the sharing structure between the ten-
sors. A component active in two or more views captures a shared response
pattern while those active in only one represent variation speciﬁc to that
tensor. The model also learns the total number of active components in
the data collection by switching all the extra h(1:M)k = 0, given K is initial-
ized to a large enough value.
The feature-level sparsity is induced via the automatic relevance de-
termination prior [ARD; 113]. The ARD shrinks the individual loadings
of W(m) and U via α(m)d,k and βl,k. This formulation regularizes the solu-
tion as well as assists in overcoming degenerate solutions. A Gibbs sam-
pler was implemented to perform the model inference, and an open source
implementation of BMTF is provided at http://research.ics.aalto.fi/
mi/software/BMTF.
The approach is general enough to include sparse Bayesian CP (CAN-
1Publication V uses slightly different notations, with the vector, matrix or tensor
nature of a symbol being deﬁned entirely by its subscripts. Here we use the given
notation in the interest of consistency throughout the thesis.
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DECOMP/PARAFAC) factorization as a special case when only one tensor
is factorized. In this case, the formulation performs comparable to the
state of the art CP solutions and outperforms them when data has degen-
erate components. The model is simultaneously also the ﬁrst Bayesian
tensor canonical correlation analysis (CCA) method, when the data set
contains two tensors; and is validated on both simulated and real data
sets to capture the multi-view trilinear tensorial structure. In short, the
methodology allows solutions for new problems. As a key example, it
is successfully demonstrated in a novel problem setting, of collectively
decomposing toxic and gene expression responses of multiple cancers to
multiple drugs. The problem setting is a novel drug-response formula-
tion, allowing identiﬁcation of toxic drug responses that are shared by all
subtypes, as well as those speciﬁc to some cancers. The application is de-
scribed in Publication V, and an even extended formulation is presented
in section 5.3.
5.2 Bayesian coupled matrix-tensor factorization
An even more interesting problem is when multi-source data collections
include both matrices and tensors, coupled on a set of common samples.
While BMTF (section 5.1) is already equipped to solve the case when data
sets are of the same order, the case of differing orders (matrices and ten-
sors) in multi-view data sets is presented in this section. Coupled matrix-
tensor factorization methods have recently been introduced [121], how-
ever, have limited applicability. Here the ﬁrst Bayesian formulation is
presented that simultaneously extends to form a generic Multi-tensor fac-
torization (MTF) while learning the nature and cardinality of factors au-
tomatically, in a data-driven fashion.
The multi-view coupled matrix-tensor factorization problem is stud-
ied here for multiple coupled matrices and tensors, such that samples are
paired in two modes within the tensors while one mode of the tensors is
common with the matrices. The goal now is to perform a collective decom-
position of the matrices and tensors while segregating between the shared
and private components, irrespective of the matrix or tensor nature of the
view. This is achieved in an unsupervised way via a joint Factor Analy-
sis and CP-type decomposition of matrices and tensors, having three key
characteristics. First, the joint decomposition is characterized by a com-
mon set of latent variables Z between all the views (tensor and matrices).
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This allows the formulation to capture common patterns between tensors
and matrices, irrespective of their nature. Second, the view-speciﬁc load-
ings W(m) control which of the patterns in Z are active in each of the
views, enabling the model to ﬁnd dependencies between any subset of the
matrices or tensors. Third, only the tensor views are additionally modeled
with loadings for the third mode U allowing both matrices and tensor to
be factorized together.
Formally, given a collection of paired matrices and tensor views X (1),
. . .X (T ), with an indicator variable βt identifying the tensors (βt = 1) and
the matrices (βt = 2), the MTF model is
x
(t)
n,:,l ∼ N
(
W(t)(zn ∗ uβtl ), I(τ (t))−1
)
Z,U(1) ∼ N (0, I)
U(2) ∼ 11×K
w
(t)
d,k ∼ ht,k N
(
0, (α
(t)
d,k)
−1
)
+ (1− ht,k) δ0
ht,k ∼ Bernoulli(πk)
πk ∼ Beta(aπ, bπ)
α
(t)
d,k ∼ Gamma(aα, bα)
τ (t) ∼ Gamma(aτ , bτ ) .
Here the joint matrix and tensor decomposition is governed by the
common Z latent variables that capture the activity patterns of all ma-
trix and tensor views. The W loadings (via the spike and slab prior, ht,k)
control the possibly different number and activity of components across
all the views, irrespective of their matrix or tensor formulation. The U
captures the patterns across the tensor mode of the tensor views. The
remaining distributional assumptions are as deﬁned in section 5.1.
Generalized MTF. The coupling of matrices and tensors can be for-
mulated for all tensors, making it possible to decompose arbitrarily cou-
pled data sets. Noting that matrices are tensors of order two, a fully
extendable formulation of MTF is proposed that decomposes arbitrarily
coupled tensors (including matrices) for investigating components shared
and speciﬁc to each. The task is conceived as factorization of a large tensor
X̂ ∈ R
∑
Di×
∑
Di×
∑
Li that is made up by a block structured formulation
of all the tensors and matrices. Here a key assumption is that the dis-
tinction between samples and dimensions is removed, and each mode of
a tensor or matrix can be represented as a group or block of variables.
The factorization can then be computed using a group-sparse prior that
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controls the activity of a component in each block. A component is active
in a view only if it is active in all the corresponding blocks (i.e. modes) of
that view. Analogous to MTF a component active in two or more views is
said to be shared between them. Formally, for the combined latent block
factor loadings W ∈ R
∑
Di×K×
∑
Li , the model is deﬁned as
Xˆ:,:,l ∼ W:,:,lW:,:,l
wd,k,l ∼ hbd,k,lN (vd,kul,k, λ−1βl ) + (1− hbd,k,l)δ0
U ∼ N (0, 1)
vd,k ∼ N
(
0, (αd,k)
−1) .
Here bd denotes the block to which feature d belongs while βl denotes
whether slab l belongs to a tensor (βl = 1) or a matrix (βl = 2). The
binary variable hbd,k,l imposes the block structure for bd = 1 . . . B blocks
via a spike and slab prior, automatically learning the exact activation
proﬁles. The hbd,k,l activity patterns for each block-factor pair can then
be used to infer the shared and speciﬁc factors for each data set. The V
and U capture the trilinear CP factors, while λβl tunes the factorization
structure.
MTF performs well in simulated illustrations and its multi-view ap-
plication on novel structural toxicogenomics is discussed in section 5.3.
An open source implementation of a Gibbs sampler for MTF is provided
at http://research.ics.aalto.fi/mi/software/MTF.
5.3 Toxicogenomics dependencies
Drug responses are measured at several levels of detail and type of activ-
ity. The gene expression responses of drugs present a systems-level view,
while the toxicity summarizes the toxic behavior. Toxicogenomics aims
to identify the links between genomic measurements of the cells and the
toxicological proﬁles of drugs. These links, if uncovered can be illustrative
of the molecular mechanisms of toxicity [122]. Interestingly, the toxicoge-
nomic responses can also be analyzed together over a series of cell lines.
Such an analysis poses the hypothesis that common patterns in the ac-
tivity of genes and toxicity proﬁles of drugs can identify cellular response
mechanisms, as well as be useful in predicting the toxicity outcome of a
drug-cell treatment. The novel multi-tensor factorization methods of sec-
tions 5.1 and 5.2 model the multi-way structure of such coupled responses
for identifying the underlying relationships.
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A novel extension of the structure-response application is formulated
next. To recap, in chapter 4, the cellular responses to drugs that are
related to their structural descriptors were analyzed. The formulations
also explored which of the responses were speciﬁc to a particular cancer
type and which shared across all sub-types. In this section, the novel
hypothesis studied is that multi-source tensor formulations can identify
and predict responses that are additionally related to drugs toxicity, while
simultaneously discovering their cancer speciﬁcity and correspondence to
structural properties of the drugs.
The toxicogenomics data set contains three drug views, speciﬁcally, (i)
the differential gene expression of several drugs as measured over three
different cancers, (ii) the toxicity proﬁles of the same set of cancers and
drugs; and (iii) the structural properties that describe the drugs. The gene
expression is, therefore, a tensor of drugs× cancers× genes, while toxicity
a tensor of drugs× cancers× toxicity_measures, and structural properties
a matrix of drugs × descriptors. The expression and toxicity data sets
come from CMap and NCI60 respectively and are processed as described
in Chapter 3. For gene expression, the most varying genes are selected
for a targeted analysis while the toxicity data comprises of three different
toxicity measurements for each of the corresponding drug-cell pairs. The
FCFP4 (section 3.3.1) are used for representing the structural properties
of the drugs. The three data sets are paired on a common identity of 73
drugs.
MTF run with K = 30 successfully identiﬁed three drug-response
components shared between all the views, demonstrating that the hy-
pothesized structure exists and can be modeled with principled solutions.
Several empty components were found indicating that the model can ef-
fectively learn the cardinality of the data. The model demonstrates its
interpretive power that comes both from the component-view activities,
which enable easier component identiﬁcation then matrix methods, and
by using the latent variables Z,U and W(m) for collective component vi-
sualization schemes.
To validate the model the joint components were interpreted, reveal-
ing both recently discovered ﬁndings, as well as those with potential for
new biological discoveries of impact. The strongest component shows a
response that is primarily driven by three structurally analogous drugs
(geldanamycin, tanespimycin, and alvespimycin), all of which belong to
the same class of HSP90 inhibitors. The component indicates that the
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drugs are inducing an HSP response of the cells (by up-regulation of HSP
genes) in all the three cancers, and is linked to the toxicity indicator GI50
(Growth Inhibition of 50%). It is well-known that the HSP90 protein is a
molecular chaperone that stabilizes a variety of other proteins, including
those that are crucial for the survival of cancer cells [123]. The HSP90
inhibitors bind to the protein resulting in a loss of function, because of
which they have also been evaluated for their therapeutic efﬁcacy in can-
cers [116, 124]. The component, therefore, presents a well known HSP90
response of cancer cells. The remaining components detailed in Publica-
tion VI also ﬁnd well-formed ﬁndings though with potential novel impli-
cations. Publication V studied a subset of the problem using BMTF with
gene expression, and toxicity data sets only, ﬁnding meaningful results.
The models were also validated quantitatively to assess if principled
handling of multi-view multi-way structure in the data impacts the pre-
dictive performance. The performance was measured as RMSE (root mean
squared error) of predicting missing data points and compared with state
or the art multi-view matrix, as well as coupled matrix-tensor methods.
The experiments veriﬁed that MTF and BMTF were able to predict the
toxic response to drugs over multiple cancers signiﬁcantly better than the
existing alternatives. In summary, the principled models can decompose
the novel drug-disease-response relationships more accurately and enable
solutions for new applications. For example, they open up a new direction
for QSAR modelers to integrate high-dimensional multi-way data sources
for predictive analysis. For medicinal chemists, it makes it possible to ex-
plore the functional mechanisms and polypharmacology for a particular
disease and response type, in a data-driven fashion.
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6. Discussion and conclusions
Returning to the hypothesis posed at the beginning of this thesis, it is
now possible to state that component-based dependency modeling meth-
ods can be used to uncover informative structure-response links and novel
mechanisms of drug action, by taking advantage of the structure in all the
data sets. The proposed methods were able to extract interesting relation-
ships and segregate dependencies between multiple data sets from those
speciﬁc to only one data set (noise, in this case).
This thesis has presented several novel multi-source methods each
for different but increasingly complex and novel formulations of drug re-
sponse analyses, demonstrating that it is important to take the appro-
priate structure of the data sets into account. Speciﬁcally, the multi-view
models make it possible to discover interactions and mechanisms that can
not be learned from individual measurement sources. Consequently, this
research has shown that the multi-view approach not only discovers po-
tentially novel biological ﬁndings but also identiﬁes dependencies that are
more informative quantitatively as well as qualitatively.
The second major ﬁnding of this thesis was that when the measure-
ments come from multiple variables of interest as well as multiple paired
response types, models that handle the paired multi-way structure work
the best. This dissertation presented new problem formulations of multi-
view tensor factorization and multi-tensor factorization along with the
models for solving them. These studies generate several contributions to
the current literature. First, the BMTF work contributed to the existing
domain of tensor factorizations by providing a Bayesian method similar to
multi-set CCA, but for tensors. Second, MTF extends the Bayesian tensor
literature by allowing tensors of different orders and arbitrary coupling
to be factorized for links shared and speciﬁc to each. These methods have
validated that principled handling of the multi-mode multi-source struct-
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ure is more accurate than the simpler alternatives. Finally, some of the
limitations of single tensor factorizations were also removed, improving
the current state of the art.
One of the more signiﬁcant and novel ﬁndings to emerge from this
thesis is that structure-response relationships of drugs can be studied sys-
tematically on a genome-wide level, using component-based approaches.
To this end, data-driven models were learned from global proﬁling datasets,
to identify the relationships between chemical features and biological re-
sponses. The studies presented in this dissertation have shown that anal-
ysis of drug compounds against a set of chemical descriptors and genome-
wide measurements can be done by extracting a set of latent representa-
tions, which highlight features in the chemical descriptor set that account
for differential biological changes in responses. Given the data-driven na-
ture of the presented studies, the components capture drug-response links
that are not constrained to known target information; therefore, many
components capture potentially novel but still unidentiﬁed mechanisms
of action. The proposed methods provide a systematic way to identify the
links between the structural properties of drugs and the cell-speciﬁc gene
expression and toxicity responses. Consequently, a potential implication
of this thesis could be the possibility to assist drug designers to tailor com-
pounds for matching the desired response patterns. It also opens up the
opportunity for medicinal chemists to better understand the functional
mechanisms of drug structures. In summary, this research moves a step
further for assisting the targeted interventions of drugs.
Therefore, this thesis produces progress in both machine learning and
molecular biology, emphasizing that by bridging fragmented disciplines
interdisciplinary research plays an important role, not only in achieving
the joint goals, but also in generating ideas for scientiﬁc advances within
each.
This dissertation has opened up several possibilities for further inves-
tigation both in applications and methods development. The novel multi-
view and multi-mode methods developed in this thesis may be applied to
any other ﬁeld, where systematic exploration of dependencies in partly
related data sets is of interest. For example, they can be used in compu-
tational neuroimaging where it could be interesting to learn the relation-
ships between a stimulus, its annotations, and the corresponding brain
measurements. Such studies could help to understand the functional re-
gions of the brain better. Another example could be computational social
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sciences where modeling of user interactions can be studied using data
from social apparatus such as Facebook, Twitter, and SMS. Such explo-
rations could seek insights into a host of issues such as behaviors, norms,
privacy concerns, and their inter-relationships.
Given the success of these ﬁrst genome-wide and multi-disease structure-
response decompositions, further research in this ﬁeld would greatly as-
sist in generalizing the patterns and exploring them for potential drug
efﬁcacies. One line of action for the generalizations could be an expansion
to large-scale analyses with the data resources similar to that of LINCS,
as they become fully available. For efﬁcacies, it would be interesting for
biological chemists to explore the plausible ﬁndings in the lab that the
methods hypothesize for novel indications. As the results also demon-
strated that integrating multiple data sources improves drug characteri-
zation, a recommended direction is to adapt and explore multi-source drug
characterization further in practice.
The thesis also opens up new solutions for the existing questions in
molecular biology. For example, it would be interesting to explore if the
multi-tensor assumptions are useful in studying responses of several or-
ganisms. This can potentially be used to study which of the responses
translate across organisms while segregating them from those which do
not. Such ﬁndings can allow systematic quantiﬁcation of the effects that
can be translated from model organisms.
On the machine learning front, a natural direction is to postulate the
new multi-view matrix and tensor models for exponential family distri-
butions, increasing the scope of the methods. The choice of underlying
factorization assumptions can be worthwhile to study. For example, it can
be interesting to explore the new model formulations for incorporating
biological pathway and target knowledge. A plausible way might be to
develop informative priors to incorporate the knowledge. This approach
could potentially support in building informative hypothesis for the data-
driven analysis. Also, the technical choices and sparsity assumptions of
the model’s may be improved further, as needed by an application.
In summary, the thesis contributes data-driven methods to analyze
the relationships between differential genome-wide responses of compounds
and their structural properties while demonstrating their practical poten-
tial. This is a valuable scientiﬁc advancement because understanding the
correlation between the structure of compounds and the differential re-
sponses of a particular disease can assist lead optimization efforts.
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